Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
10.12
+0.01 (0.10%)
At close: Nov 7, 2025, 4:00 PM EST
10.32
+0.20 (1.98%)
After-hours: Nov 7, 2025, 7:48 PM EST
Viatris Revenue
Viatris had revenue of $3.76B in the quarter ending September 30, 2025, with 0.23% growth. This brings the company's revenue in the last twelve months to $14.12B, down -6.14% year-over-year. In the year 2024, Viatris had annual revenue of $14.74B, down -4.46%.
Revenue (ttm)
$14.12B
Revenue Growth
-6.14%
P/S Ratio
0.85
Revenue / Employee
$441,388
Employees
32,000
Market Cap
11.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.74B | -687.60M | -4.46% |
| Dec 31, 2023 | 15.43B | -835.80M | -5.14% |
| Dec 31, 2022 | 16.26B | -1.62B | -9.08% |
| Dec 31, 2021 | 17.89B | 5.94B | 49.73% |
| Dec 31, 2020 | 11.95B | 445.50M | 3.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VTRS News
- 2 days ago - Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs - Reuters
- 3 days ago - Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance - PRNewsWire
- 5 days ago - Viatris Announces Quarterly Dividend - PRNewsWire
- 10 days ago - Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
- 22 days ago - Teva Vs. Viatris: Who Will Dominate In President Trump's America? - Seeking Alpha
- 24 days ago - Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region - PRNewsWire
- 27 days ago - Viatris to Participate in Upcoming Investor Conferences - PRNewsWire